Hidden danger: why some patients can't shake COVID-19

NCT ID NCT06576102

Completed Knowledge-focused Sponsor: Maddalena Giannella Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tracked 204 patients with blood cancers or those on certain immune-suppressing treatments to see how often COVID-19 infection persists for 21 days or more. Researchers also looked for factors that make a long infection more likely. The goal was to better understand who is at risk, not to test a new treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for B-CELL MALIGNANCIES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell neoplasm COVID-19 long COVID-19

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

B-CELL MALIGNANCIES PERSISTENT COVID-19

Contacts and locations

Locations

AOUI Verona

Verona, Verona, 37126, Italy
Hospital Virgen Macarena

Seville, Seville, 41009, Spain
IRCCS Humanitas

Milan, Milan, 20089, Italy
IRCCS INMI L. Spallanzani

Roma, Roma, 00149, Italy
Irccs Aoubo

Bologna, Bologna, 40138, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.